Anti-IgLON5 Disease Masquerading as a Cocaine-Induced Hyperkinetic Movement Disorder: A Case Report

A substance exposure that coincides with an acute neurological presentation can explain the exacerbation without explaining the underlying disease. We describe a 43-year-old man who presented with two hours of transient left-sided numbness, dysarthria, and word-finding difficulty, together with abnormal involuntary movements, progressive sleep disturbance, and subjective cognitive decline. Examination showed ptosis, choreiform-appearing movements of the hands, feet, and face, and stereotyped left facial movements. Neuroimaging and electroencephalography were unrevealing. Metabolic, inflammatory, and toxicological screening was unremarkable. He reported cocaine use shortly before admission, and an acute worsening with spontaneous nonrhythmic jerks was attributed to a substance-induced movement disorder. He was discharged while a serum autoimmune panel remained pending. The panel returned positive for IgLON5 antibodies at a titer of 1:1920, and he was readmitted. On more detailed questioning, sleep disturbance had begun approximately three years earlier, and nocturnal hyperkinetic movements with vocalization and dream enactment had developed over the preceding months. Cerebrospinal fluid demonstrated a mild lymphocytic pleocytosis with IgLON5 antibodies positive at 1:128, and serum neurofilament light chain was elevated at 23.6 pg/mL. He was treated with intravenous methylprednisolone followed by intravenous immunoglobulin. The choreiform movements and nocturnal behaviors resolved, and his sleep improved during treatment, although this improvement in insomnia was not sustained. At follow-up three months after presentation, his movement, speech, and cognitive symptoms remained in remission on maintenance immunoglobulin, although insomnia had returned to its pretreatment level. A temporally associated substance exposure may explain an exacerbation without explaining the underlying neurological disease.

Authors

Publication Details

Journal
Cureus
Published
2026-11-21
DOI
https://doi.org/10.7759/cureus.120043
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anti-IgLON5 Disease Masquerading as a Cocaine-Induced Hyperkinetic Movement Disorder: A Case Report

Jawad Abou Zeid, Robert Ungerer, Patrick Sleiman, Saniya Ahmed
Cureus
Autoimmune Neurological Disorders and Treatments
article

Anti-IgLON5 Disease Masquerading as a Cocaine-Induced Hyperkinetic Movement Disorder: A Case Report

Jawad Abou Zeid, Robert Ungerer, Patrick Sleiman, Saniya Ahmed
article en

Abstract

A substance exposure that coincides with an acute neurological presentation can explain the exacerbation without explaining the underlying disease. We describe a 43-year-old man who presented with two hours of transient left-sided numbness, dysarthria, and word-finding difficulty, together with abnormal involuntary movements, progressive sleep disturbance, and subjective cognitive decline. Examination showed ptosis, choreiform-appearing movements of the hands, feet, and face, and stereotyped left facial movements. Neuroimaging and electroencephalography were unrevealing. Metabolic, inflammatory, and toxicological screening was unremarkable. He reported cocaine use shortly before admission, and an acute worsening with spontaneous nonrhythmic jerks was attributed to a substance-induced movement disorder. He was discharged while a serum autoimmune panel remained pending. The panel returned positive for IgLON5 antibodies at a titer of 1:1920, and he was readmitted. On more detailed questioning, sleep disturbance had begun approximately three years earlier, and nocturnal hyperkinetic movements with vocalization and dream enactment had developed over the preceding months. Cerebrospinal fluid demonstrated a mild lymphocytic pleocytosis with IgLON5 antibodies positive at 1:128, and serum neurofilament light chain was elevated at 23.6 pg/mL. He was treated with intravenous methylprednisolone followed by intravenous immunoglobulin. The choreiform movements and nocturnal behaviors resolved, and his sleep improved during treatment, although this improvement in insomnia was not sustained. At follow-up three months after presentation, his movement, speech, and cognitive symptoms remained in remission on maintenance immunoglobulin, although insomnia had returned to its pretreatment level. A temporally associated substance exposure may explain an exacerbation without explaining the underlying neurological disease.

Cureus
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon